TheraRadar
Data updated: May 26, 2026

LODINE (etodolac)

Immunology Approved 1991-01-31
2
Indications
--
Phase 3 Trials
35
Years on Market

Details

Status
Discontinued
First Approved
1991-01-31
Routes
ORAL
Dosage Forms
TABLET, CAPSULE

Companies

Active Ingredient: ETODOLAC

LODINE Approval History

1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
92 FDA actions from 1991 to 2007
Oct 2007 SUPPL
Label · Labeling
Jan 2006 SUPPL
Label · Labeling
May 2005 SUPPL
Label · Labeling

What LODINE Treats

2 FDA approvals

Originally approved for its first indication in 1991 . Covers 2 distinct patient populations.

  • Other (2)
📋

Clinical Trial Registry

6 trials
Trial Sponsor ID Phase Status Title
NCT03127592 FDCETCB-III ETCAPS0317OR-III Ph 3 terminated Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
NCT01198834 MRX-7EAT-1005 Ph 3 completed MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains
NCT02881619 UFS Ph 4 completed Etodolac and Post-bleaching Sensitivity
NCT01118572 177-CL-102 Ph 3 completed A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients
NCT01749228 Ipca/VIN-11/416 Ph 1 completed Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition
NCT01746719 Ipca/VIN-11/415 Ph 1 completed Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LODINE FDA Label Details

Track LODINE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.